Terms: = Prostate cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Diagnosis
7520 results:
1. A Community-Based prostate cancer Screening and Education Program for Asian American Men in Medically Underserved Communities.
Cho D; Gor B; Hwang H; Wang X; Hernandez M; Jones LA; Frost J; Roberson P; Pettaway CA
Int J Environ Res Public Health; 2024 Mar; 21(4):. PubMed ID: 38673327
[TBL] [Abstract] [Full Text] [Related]
2. Developing a Novel Enzalutamide-Resistant prostate cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract] [Full Text] [Related]
3. [Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].
Jin Y; Zhai ZW; Sun LT; Xia PD; Hu H; Jiang CQ; Zhao BC; Qu H; Qian Q; Dai Y; Yao HW; Wang ZJ; Han JG
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):403-411. PubMed ID: 38644246
[No Abstract] [Full Text] [Related]
4. Patterns of Care for Medicare Beneficiaries With Metastatic prostate cancer.
Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2024 May; 11(3):489-497. PubMed ID: 38640419
[TBL] [Abstract] [Full Text] [Related]
5. [Application of 1470 nm semiconductor laser in the treatment of benign prostatic hyperplasia in ultra-aged patients].
Wu D; Yi XM; Wei HX; Zhang KX; Shi CJ; Shi XQ; Xu ZY; Fu D
Zhonghua Nan Ke Xue; 2023 Sep; 29(9):831-836. PubMed ID: 38639597
[TBL] [Abstract] [Full Text] [Related]
6. prostate cancer, Version 3.2024.
Schaeffer EM; Srinivas S; Adra N; An Y; Bitting R; Chapin B; Cheng HH; D'Amico AV; Desai N; Dorff T; Eastham JA; Farrington TA; Gao X; Gupta S; Guzzo T; Ippolito JE; Karnes RJ; Kuettel MR; Lang JM; Lotan T; McKay RR; Morgan T; Pow-Sang JM; Reiter R; Roach M; Robin T; Rosenfeld S; Shabsigh A; Spratt D; Szmulewitz R; Teply BA; Tward J; Valicenti R; Wong JK; Snedeker J; Freedman-Cass DA
J Natl Compr Canc Netw; 2024 Apr; 22(3):140-150. PubMed ID: 38626801
[TBL] [Abstract] [Full Text] [Related]
7. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy].
Hu J; Zhao XD; Zhou YL; Dong N; Ma MF; Chen YH; Sheng ZC; Dong J; He CQ; Xu S
Zhonghua Nan Ke Xue; 2023 Aug; 29(8):729-735. PubMed ID: 38619521
[TBL] [Abstract] [Full Text] [Related]
9. [A single center study：An analysis of the safety and validity of delaying repeated biopsy for patients with atypical small acinar proliferation].
Ji WT; Liu DC; Cui WL; Hu Y; Wang Y; Tan JF
Zhonghua Nan Ke Xue; 2023 May; 29(5):414-419. PubMed ID: 38602757
[TBL] [Abstract] [Full Text] [Related]
10. Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study.
Støyten M; Knutsen T; Stikbakke E; Agledahl I; Wilsgaard T; Eggen AE; Richardsen E; Giovannucci E; Thune I; Haugnes HS
Acta Oncol; 2024 Apr; 63():154-163. PubMed ID: 38591351
[TBL] [Abstract] [Full Text] [Related]
11. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
12. Assessment of the accuracy of biparametric MRI/TRUS fusion-guided biopsy for index tumor evaluation using postoperative pathology specimens.
Shimizu R; Morizane S; Yamamoto A; Yamane H; Nishikawa R; Kimura Y; Yamaguchi N; Hikita K; Honda M; Takenaka A
BMC Urol; 2024 Apr; 24(1):79. PubMed ID: 38575912
[TBL] [Abstract] [Full Text] [Related]
13. The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service.
Lim AR; Park W; Moon SJ; Kim MS; Lee S
BMC Health Serv Res; 2024 Apr; 24(1):412. PubMed ID: 38566103
[TBL] [Abstract] [Full Text] [Related]
14. Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
Dong Q; Wang C; Shen D; Ma Y; Zhang B; Xu S; Tao T; Xiao J
Prostate; 2024 Jun; 84(8):780-787. PubMed ID: 38558415
[TBL] [Abstract] [Full Text] [Related]
15. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract] [Full Text] [Related]
16. A Novel DNA Aptamer Probe Recognizing Castration Resistant prostate cancer in vitro and in vivo Based on Cell-SELEX.
Zhong J; Liu D; Yang Q; Ding J; Chen X
Drug Des Devel Ther; 2024; 18():859-870. PubMed ID: 38524880
[TBL] [Abstract] [Full Text] [Related]
17. Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression.
Sadasivan SM; Loveless IM; Chen Y; Gupta NS; Sanii R; Bobbitt KR; Chitale DA; Williamson SR; Rundle AG; Rybicki BA
Cancer Med; 2024 Mar; 13(6):e7118. PubMed ID: 38523528
[TBL] [Abstract] [Full Text] [Related]
18. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
19. ReHoGCNES-MDA: prediction of miRNA-disease associations using homogenous graph convolutional networks based on regular graph with random edge sampler.
Zhang Y; Chu Y; Lin S; Xiong Y; Wei DQ
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38517693
[TBL] [Abstract] [Full Text] [Related]
20. Adrenal-Permissive Germline HSD3B1 Allele and prostate cancer Outcomes.
McKay RR; Nelson TJ; Pagadala MS; Teerlink CC; Gao A; Bryant AK; Agiri FY; Guram K; Thompson RF; Pridgen KM; Seibert TM; Lee KM; Carter H; Lynch JA; Hauger RL; Rose BS
JAMA Netw Open; 2024 Mar; 7(3):e242976. PubMed ID: 38506808
[TBL] [Abstract] [Full Text] [Related]
[Next]
